ARAY Key Stats
- Accuray Incorporated to Present at 2013 Jefferies Global Healthcare Conference PR Newswire May 22
- InPlay: Accuray new data validates CyberKnife SBRT for prostate cancer treatment May 21
- New Data Validates CyberKnife SBRT for Prostate Cancer Treatment PR Newswire May 21
- ACCURAY INC Financials May 17
- Why Accuray's Earnings May Be Less Than Awesome Fool May 17
- Are the Earnings at Accuray Hiding Something? Fool May 16
- Earnings Volatility Drives These Healthcare Stocks in a New Direction May 12
- ACCURAY INC Files SEC form 10-Q, Quarterly Report May 9
- Accuray Lags 3Q Earnings Est May 8
- Accuray Misses on the Top and Bottom Lines May 8
ARAY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Accuray is down 14.40% over the last year vs S&P 500 Total Return up 28.33%, Abiomed down 3.25%, and Cyberonics up 26.72%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for ARAY
Pro Report PDF for ARAY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ARAY Pro Report PDF
Pro Strategies Featuring ARAY
Did Accuray make it into our Pro Portfolio Strategies?